kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
32
JPY
0
(0.00%)
Mar 13, 3:30 pm JST
0.20
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
31.9
Mar 13, 11:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.92
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
32 JPY 0.20 USD
Previous Close Mar 12
32 JPY 0.20 USD
High Mar 13, 9:00 am
33 JPY 0.20 USD
Low Mar 13, 9:09 am
31 JPY 0.19 USD
Volume
35,086,400
Trading Value
1.12B JPY 7.04M USD
VWAP
31.99 JPY 0.2 USD
Minimum Trading Value
3,200 JPY 20 USD
Market Cap
8.63B JPY 0.05B USD
Number of Trades
173
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
352
1-Year High Jun 27, 2025
2,772
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,550,000 21,457,200 13.84
Feb 27, 2026 2,141,800 21,829,000 10.19
Feb 20, 2026 1,210,200 20,284,600 16.76
Feb 13, 2026 1,190,400 20,564,300 17.28
Feb 6, 2026 1,629,600 21,270,200 13.05
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.